Form 4: Revolution Medicines CMO Sells Shares for Tax

Revolution Medicines' Chief Medical Officer, Wei Lin, sold 2,073 shares of common stock for tax withholding purposes under a pre-arranged 10b5-1 plan.

Summary

• Wei Lin, Chief Medical Officer of Revolution Medicines, Inc. (RVMD), reported a sale of common stock.
• The transaction involved the disposition of 2,073 shares of common stock at a price of $99.4804 per share.
• The sale was executed on March 17, 2026, pursuant to a Rule 10b5-1 instruction letter adopted on December 23, 2024.
• The purpose of the sale was to satisfy tax withholding obligations upon the vesting of restricted stock units (RSUs) after March 15, 2025.
• Following this transaction, Wei Lin beneficially owns 101,366 shares, which includes 62,050 RSUs.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. The sale is a routine, pre-scheduled transaction for tax purposes under a 10b5-1 plan, which typically does not reflect a change in the insider's sentiment towards the company's prospects.

Positives

• NA

Negatives

• NA

Risks

• No new risks are identified in this filing, which primarily reports an insider stock transaction.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Management Comments

• NA

Industry Context

StockSavvy.ai notes that insider sales under Rule 10b5-1 plans are a common practice for executives to manage personal finances, diversify holdings, and cover tax obligations associated with equity compensation. Such pre-arranged sales typically do not signal a change in management's operational outlook or confidence in the company's strategic direction, distinguishing them from discretionary sales that might imply a shift in sentiment.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• NA

Stakeholder Impact

• Minimal direct impact on shareholders, employees, customers, suppliers, or creditors as this is a routine, pre-scheduled insider sale for tax purposes and not indicative of operational changes or financial distress.

Next Steps

• NA

Key Dates

Recommendation

This Form 4 filing details a routine, pre-scheduled sale of shares by a Chief Medical Officer for tax withholding purposes under a 10b5-1 plan. Such transactions are common and generally do not reflect a change in the insider's view of the company's fundamentals or future prospects. Therefore, it provides no new information to warrant a change in investment recommendation.

Keywords

Revolution Medicines, RVMD, Insider Trading, Form 4, Stock Sale, Chief Medical Officer, Wei Lin, 10b5-1 Plan, Tax Withholding, Restricted Stock Units